"Science-Driven Precision Analysis"
One-Stop Research Solutions from Cells and Tissues to Animal Models

Jireh BioPath is an R&D-driven biotechnology company focused on antiviral drug development. We aim to build a broad-spectrum therapeutic platform for infectious and inflammatory diseases through first-in-class therapeutics targeting innate immune sensors.

We also provide integrated preclinical CRO services spanning histopathology, cell-based assays, and animal studies, supporting our clients throughout the research and preclinical drug development process.

About Jireh BioPath
Company
Jireh BioPath Co., Ltd.
CEO
SangJoon Lee
Established
September 2025
Address
Room 514, Building 251, 50 UNIST-gil, Eonyang-eup, Ulju-gun, Ulsan, Republic of Korea
TEL
+82-52-217-3372
FAX
+82-52-217-2490
Our Service
Integrated One-Stop Research Service from Histopathology and Clinical Pathology to In Vitro & In Vivo Studies and Animal Studies
Histopathology Services
Comprehensive histopathology services, from tissue processing and staining to TMA construction and in-depth pathological analysis.
  • FFPE block
  • H&E
  • IHC
  • Special Staining
  • IF
  • TMA
Clinical Pathology Services
Quantitative assessment of biological conditions through blood and body fluid analysis.
  • Hematology
  • Biochemistry
  • Immunoassays
In Vitro Studies
Evaluation of drug efficacy, toxicity, and mechanisms of action using cell-based assays.
  • Cytotoxicity
  • Protein Expression
  • Gene Expression
  • Viral Infection
  • Cell Permeability
  • Cytokine Assays
  • ELISA
In Vivo Studies
Evaluation of preclinical efficacy and safety using various disease models.
  • Viral Infection
  • Cancer
  • Alcoholic Liver Disease
  • Drug Toxicity